Aktis Oncology, Inc. (AKTS)

NASDAQ: AKTS · USD

$16.8

+0.39 (+2.4%)· Recorded snapshot

Market cap	936.9M
Revenue (ttm)	10.1M
Net income (ttm)	-73.1M
EPS (ttm)	-$2.77
Shares out	55.6M
Volume	144,808

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 10.1M
Net income (ttm): -73.1M
EPS (ttm): -$2.77
Market cap: 936.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Manter

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROICn/a

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All AKTS indicators

Market & fundamental data

Available fields

170

Groups with data

Currency

USD

Showing 170 of 170 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002035832
Company name	Aktis Oncology, Inc.
Country	United States
Country code	US
CUSIP number	01021M104
Earnings date	2026-11-12
Earnings time	bmo
Employees	79
Enterprise value	$430.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2020
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2026-01-09
Is primary listing	Yes
Is SPAC	No
ISIN number	US01021M1045
Last 10-K release date	2026-03-30
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$936.9M
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$16.85
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AKTS
U.S. state	Massachusetts
Website	https://www.aktisoncology.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-16.45%
EV/Sales	42.36x
FCF / EV yield	-19.85%
FCF yield	-9.07%
Forward EV/Sales	54.55x
Forward P/S	119.33x
P/B ratio	1.88x
P/S ratio	92.66x
Price / tangible book value	1.92x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-866.63%
Pretax margin	-727.04%
Profit per employee	$-925,823
Revenue per employee	$127,342
ROCE	-16.59%
SBC / revenue	85.71%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Net income growth years	0
Revenue growth	576.53%
Revenue growth (Q)	111.37%
Revenue growth (QoQ)	4.87%
Revenue growth quarters	3
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9.3M
Depreciation and amortization	$2.8M
EBIT	$-87.2M
EBITDA	$-84.4M
EPS	$-2.77
FCF per share	$-1.52
Financing cash flow	$337M
Free cash flow	$-84.6M
Free cash flow minus SBC	$-93.2M
Gross profit	$-68.2M
Investing cash flow	$-289.4M
Net cash flow	$-27.7M
Net income	$-73.1M
Operating cash flow minus SBC	$-83.9M
Operating income	$-87.2M
Revenue	$10.1M
Stock-based compensation	$8.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	8.98
Book value per share	$8.76
Debt / equity	0.02
Long-term assets	$33.1M
Long-term liabilities	$40.6M
Net cash (debt)	$506.1M
Net cash / market cap	54.29%
Net cash growth	77.47%
Net debt / equity	-1.04
Piotroski F-Score	2
Property, plant and equipment	$28.2M
Shareholders' equity	$484.8M
Tangible book value	$484.8M
Tangible book value per share	$8.76
Total assets	$557.6M
Total cash	$517.3M
Total debt	$11.2M
Total liabilities	$72.8M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$524.5M
Current liabilities	$32.1M
Current ratio	16.33
Net working capital	$-23.4M
Quick ratio	16.17
Working capital	$492.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-3,649.41%
Dividend yield	0%
Shareholder yield	-3,649.41%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$21.58
1D price change	2.4%
1M price change	-13.3%
1M total return	-13.3%
1W price change	2.59%
1W total return	2.59%
20-day SMA	$16.90
200-day SMA	$21.06
3M price change	-30.42%
3M total return	-30.42%
50-day SMA	$20.90
50-day SMA vs 200-day SMA	50under200
52-week high	$34.19
52-week high date	2026-06-30
52-week low	$14.72
52-week low date	2026-03-30
6M price change	-16.15%
6M total return	-16.15%
All-time high	$34.19
All-time high date	2026-06-30
All-time low	$14.72
All-time low date	2026-03-30
Average true range (ATR)	$0.97
Average volume	340K
Beta (1Y)	2.41
Change from 52-week high	-50.73%
Change from 52-week low	14.44%
Change from all-time high	-50.73%
Change from all-time low	14.44%
Change from open	0.33%
Day's gap	2.07%
Dollar volume	$2.4M
High price	$17.00
Low price	$16.64
Monthly RSI	0
Open price	$16.79
Position in 52-week range	56.94%
Premarket change	1.22%
Premarket close	$16.45
Premarket price	$16.65
Previous close	$16.45
Price vs 150-day SMA	-21.93%
Price vs 20-day SMA	-0.32%
Price vs 200-day SMA	-20.02%
Price vs 50-day SMA	-19.39%
Relative volume	0.43
Return from IPO open	-37.93%
Return from IPO price	-6.89%
RSI	41.86
Sharpe ratio	-0.25
Sortino ratio	-0.27
Volume	144.8K
Weekly RSI	40.64

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	28.6M
Float percentage	51.4%
Shares change (QoQ)	13.72%
Shares change (YoY)	3,649.41%
Shares held by insiders	0.46%
Shares held by institutions	43.35%
Shares outstanding	55.6M
Short % of float	15.09%
Short % of shares	7.76%
Short ratio	10.1 days

Deeper analysis on AKTS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AKTS report

Is a complete AKTS research report available?

No complete published report is available for Aktis Oncology, Inc. (AKTS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Aktis Oncology, Inc. (AKTS)

Price

Financial snapshot

Fair-value bridge

Latest news · AKTS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AKTS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AKTS

Frequently asked questions